Why Haemonetics is on investors’ radar today Haemonetics (HAE) is drawing attention after recent share performance that includes a month decline of about 3% and a past 3 months drop of roughly 24%, ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have seen decent returns lately as healthcare ...

Haemonetics ( (HAE)) has shared an announcement. On March 2, 2026, Haemonetics Corporation fully repaid at maturity its outstanding 0.00% Convertible Senior Notes due 2026, paying $300 million in cash ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

9 analysts have shared their evaluations of Haemonetics (NYSE:HAE) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 ...

Detailed price information for Haemonetics Corp (HAE-N) from The Globe and Mail including charting and trades.

Haemonetics Corp. has announced it has completed the acquisition of the business assets of Pall Corp.’s blood collection, filtration and processing product lines, according to a news release. The ...